A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
A missense variant in GLP1R associated with lower fasting glucose levels and protective against T2D is associated with lower risk of coronary heart disease, suggesting that GLP1R agonists are not associated with an unacceptable increase in cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Self-citationPrevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“Thus, while our results offer insight into the effects ofGLP1Ragonists, theydonotnecessarilyapplyto other agents targeting the incretin pathway through different mechanisms, such as by DPP-4 inhibition ( 41 ).”
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Self-citationSequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Self-citationDiabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Self-citation
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
“A low-frequency missense variant Ala316Thr; rs10305492 in the GLP1R gene wasassociatedwith fastingglucoseanda lower risk of T2D (Scott et al., 2016), findings independently confirmed in separate human cohorts (Wessel et al., 2015).”
BackgroundInfluentialThe druggable genome and support for target identification and validation in drug development
Finan, C., Gaulton, A., Kruger, F. A., Lumbers, R. T., Shah, T., Engmann, J., Galver, L., Kelley, R., Karlsson, A., Santos, R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1166 · Cited by 1,026
The trans-ancestral genomic architecture of glycemic traits
Chen, J., Spracklen, C. N., Marenne, G., Varshney, A., Corbin, L. J., Luan, J., Willems, S. M., Wu, Y., Zhang, X., Horikoshi, M., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00852-9 · Cited by 793
Self-citationThe Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Exome sequencing and characterization of 49,960 individuals in the UK Biobank
Van Hout, C. V., Tachmazidou, I., Backman, J. D., Hoffman, J. D., Liu, D., Pandey, A. K., Gonzaga-Jauregui, C., Khalid, S., Ye, B., Banerjee, N., et al. (2020) · Nature · doi:10.1038/s41586-020-2853-0 · Cited by 561
Self-citationUsing genetic data to strengthen causal inference in observational research
Pingault, J.-B., O’Reilly, P. F., Schoeler, T., Ploubidis, G. B., Rijsdijk, F., & Dudbridge, F. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0020-3 · Cited by 444
Lotta, L. A., Scott, R. A., Sharp, S. J., Burgess, S., Luan, J., Tillin, T., Schmidt, A. F., Imamura, F., Stewart, I. D., Perry, J. R. B., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002179 · Cited by 417
Self-citationLotta, L. A., Sharp, S. J., Burgess, S., Perry, J. R. B., Stewart, I. D., Willems, S. M., Luan, J., Ardanaz, E., Arriola, L., Balkau, B., et al. (2016) · JAMA · doi:10.1001/jama.2016.14568 · Cited by 394
“Diastolic 87 (11) 82 (11) 82 (10) 82 (10) NA NA”
Self-citationDiabetes mellitus—Progress and opportunities in the evolving epidemic
Abel, E. D., Gloyn, A. L., Evans-Molina, C., Joseph, J. J., Misra, S., Pajvani, U. B., Simcox, J., Susztak, K., & Drucker, D. J. (2024) · Cell · doi:10.1016/j.cell.2024.06.029 · Cited by 292
Zhao, W., Rasheed, A., Tikkanen, E., Lee, J.-J., Butterworth, A. S., Howson, J. M. M., Assimes, T. L., Chowdhury, R., Orho-Melander, M., Damrauer, S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3943 · Cited by 274
Self-citationMendelian randomization for studying the effects of perturbing drug targets
Gill, D., Georgakis, M. K., Walker, V. M., Schmidt, A. F., Gkatzionis, A., Freitag, D. F., Finan, C., Hingorani, A. D., Howson, J. M. M., Burgess, S., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16544.1 · Cited by 266
Self-citationThe Metabolic Syndrome in Men study: a resource for studies of metabolic and cardiovascular diseases
Laakso, M., Kuusisto, J., Stančáková, A., Kuulasmaa, T., Pajukanta, P., Lusis, A. J., Collins, F. S., Mohlke, K. L., & Boehnke, M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.o072629 · Cited by 204
“associated with decreased fasting glucose levels and the risk of T2D, consistent with GLP1R agonist therapies (38).”
BackgroundSelf-citationHolmes, M. V., Richardson, T. G., Ference, B. A., Davies, N. M., & Davey Smith, G. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00493-1 · Cited by 184
Wilson, J. M., Lin, Y., Luo, M. J., Considine, G., Cox, A. L., Bowsman, L. M., Robins, D. A., Haupt, A., Duffin, K. L., & Ruotolo, G. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14553 · Cited by 149
“Pharmacological treatments that reduce hsCRP, including statins and anti-IL1β antibody, are associated with improved cardiovascular outcomes.13-17 In the current 26-week study, we also observed a trend for reduction in MCP-1 levels with the 10 and 15 mg doses of tirzepatide, and no changes in IL-6 levels, thus suggest…”
BackgroundInfluentialGusarova, V., O’Dushlaine, C., Teslovich, T. M., Benotti, P. N., Mirshahi, T., Gottesman, O., Van Hout, C. V., Murray, M. F., Mahajan, A., Nielsen, J. B., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04611-z · Cited by 145
Self-citationBovijn, J., Krebs, K., Chen, C.-Y., Boxall, R., Censin, J. C., Ferreira, T., Pulit, S. L., Glastonbury, C. A., Laber, S., Millwood, I. Y., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay6570 · Cited by 119
Self-citationVan Hout, C. V., Tachmazidou, I., Backman, J. D., Hoffman, J. X., Ye, B., Pandey, A. K., Gonzaga-Jauregui, C., Khalid, S., Liu, D., Banerjee, N., et al. (2019) · doi:10.1101/572347 · Cited by 110
Self-citationHeuvelman, V. D., Van Raalte, D. H., & Smits, M. M. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvz323 · Cited by 106
GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
Wilbon, S. S., & Kolonin, M. G. (2023) · Cells · doi:10.3390/cells13010065 · Cited by 101
“Interestingly, a rare missense mutation in the GLP1R appears to confer a reduced risk for coronary heart disease development [42].”
BackgroundThe Genetic Epidemiology of Type 2 Diabetes: Opportunities for Health Translation
Meigs, J. B. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1173-y · Cited by 82
GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0046 · Cited by 51
Incretins and cardiovascular disease: to the heart of type 2 diabetes?
Solini, A., Tricò, D., & Del Prato, S. (2023) · Diabetologia · doi:10.1007/s00125-023-05973-w · Cited by 32
Harlow, C. E., Gandawijaya, J., Bamford, R. A., Martin, E.-R., Wood, A. R., van der Most, P. J., Tanaka, T., Leonard, H. L., Etheridge, A. S., Innocenti, F., et al. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.08.004 · Cited by 13
Self-citation
Metadata
- Authors
- Scott, R. A., Freitag, D. F., Li, L., Chu, A. Y., Surendran, P., Young, R., Grarup, N., Stancáková, A., Chen, Y., Varga, T. V., Yaghootkar, H., Luan, J., Zhao, J. H., Willems, S. M., Wessel, J., Wang, S., Maruthur, N., Michailidou, K., Pirie, A., van der Lee, S. J., Gillson, C., Al Olama, A. A., Amouyel, P., Arriola, L., Arveiler, D., Aviles-Olmos, I., Balkau, B., Barricarte, A., Barroso, I., Garcia, S. B., Bis, J. C., Blankenberg, S., Boehnke, M., Boeing, H., Boerwinkle, E., Borecki, I. B., Bork-Jensen, J., Bowden, S., Caldas, C., Caslake, M., The CVD50 consortium, Cupples, L. A., Cruchaga, C., Czajkowski, J., den Hoed, M., Dunn, J. A., Earl, H. M., Ehret, G. B., Ferrannini, E., Ferrieres, J., Foltynie, T., Ford, I., Forouhi, N. G., Gianfagna, F., Gonzalez, C., Grioni, S., Hiller, L., Jansson, J.-H., Jørgensen, M. E., Jukema, J. W., Kaaks, R., Kee, F., Kerrison, N. D., Key, T. J., Kontto, J., Kote-Jarai, Z., Kraja, A. T., Kuulasmaa, K., Kuusisto, J., Linneberg, A., Liu, C., Marenne, G., Mohlke, K. L., Morris, A. P., Muir, K., Müller-Nurasyid, M., Munroe, P. B., Navarro, C., Nielsen, S. F., Nilsson, P. M., Nordestgaard, B. G., Packard, C. J., Palli, D., Panico, S., Peloso, G. M., Perola, M., Peters, A., Poole, C. J., Quirós, J. R., Rolandsson, O., Sacerdote, C., Salomaa, V., Sánchez, M.-J., Sattar, N., Sharp, S. J., Sims, R., Slimani, N., Smith, J. A., Thompson, D. J., Trompet, S., Tumino, R., van der A, D. L., van der Schouw, Y. T., Virtamo, J., Walker, M., Walter, K., GERAD_EC Consortium, Neurology Working Group of the Cohorts for Heart, (CHARGE), A. R. I. G. E., Alzheimer’s Disease Genetics Consortium, Pancreatic Cancer Cohort Consortium, (EPIC-CVD), E. P. I. I. C. A. N. D., EPIC-InterAct, Abraham, J. E., Amundadottir, L. T., Aponte, J. L., Butterworth, A. S., Dupuis, J., Easton, D. F., Eeles, R. A., Erdmann, J., Franks, P. W., Frayling, T. M., Hansen, T., Howson, J. M. M., Jørgensen, T., Kooner, J., Laakso, M., Langenberg, C., McCarthy, M. I., Pankow, J. S., Pedersen, O., Riboli, E., Rotter, J. I., Saleheen, D., Samani, N. J., Schunkert, H., Vollenweider, P., O’Rahilly, S., CHARGE consortium, The CHD Exome+ Consortium, CARDIOGRAM Exome Consortium, Deloukas, P., Danesh, J., Goodarzi, M. O., Kathiresan, S., Meigs, J. B., Ehm, M. G., Wareham, N. J., & Waterworth, D. M.
- Venue
- Science Translational Medicine
- Published
- 2016-06
- Volume
- 8
- Issue
- 341
- Pages
- 341ra76-341ra76
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2412937130
- Cited by
- 118
- References
- 56
- FWCI
- 12.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.